{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:05:58Z","timestamp":1786705558992,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.diabet.2019.10.003","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T01:14:31Z","timestamp":1572743671000},"page":"197-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The gut microbiota and diabetic cardiomyopathy in humans"],"prefix":"10.1016","volume":"46","author":[{"given":"M.","family":"Bastin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andreelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2019.10.003_bib0350","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2019.10.003_bib0355","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/4441022a","article-title":"Microbial ecology: human gut microbes associated with obesity","volume":"444","author":"Ley","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.diabet.2019.10.003_bib0360","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1053\/j.gastro.2016.12.048","article-title":"Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction","volume":"152","author":"Bouter","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2019.10.003_bib0365","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 19 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0370","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on Diabetes, Pre-Diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and Developed in Collaboration","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2019.10.003_bib0375","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","article-title":"High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes","volume":"55","author":"Boonman-de Winter","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2019.10.003_bib0380","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.diabet.2018.07.003","article-title":"Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways","volume":"45","author":"Joubert","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2019.10.003_bib0385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ejhf.1059","article-title":"An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology","volume":"20","author":"Louren\u00e7o","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2019.10.003_bib0390","first-page":"387","article-title":"Diabetic cardiomyopathy: is resistin a culprit?","volume":"5","author":"Lebeche","year":"2015","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.diabet.2019.10.003_bib0395","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1172\/JCI129193","article-title":"Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome","volume":"129","author":"Kita","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2019.10.003_bib0400","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3892\/etm.2014.1539","article-title":"Analysis of the association between adiponectin, adiponectin receptor 1 and diabetic cardiomyopathy","volume":"7","author":"Li","year":"2014","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.diabet.2019.10.003_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-018-0042-6","article-title":"Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy","volume":"40","author":"Knapp","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.diabet.2019.10.003_bib0410","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.lfs.2012.10.011","article-title":"Diabetic cardiomyopathy and metabolic remodeling of the heart","volume":"92","author":"Battiprolu","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.diabet.2019.10.003_bib0415","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/nm1137","article-title":"Adiponectin-mediated modulation of hypertrophic signals in the heart","volume":"10","author":"Shibata","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2019.10.003_bib0420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7150\/ijms.14141","article-title":"Role of Serum Biomarkers in Early Detection of Diabetic Cardiomyopathy in the West Virginian Population","volume":"13","author":"Shaver","year":"2016","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.diabet.2019.10.003_bib0425","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/oby.2005.215","article-title":"Association of plasma resistin levels with coronary heart disease in women","volume":"13","author":"Pischon","year":"2005","journal-title":"Obes Res"},{"key":"10.1016\/j.diabet.2019.10.003_bib0430","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1253\/circj.71.460","article-title":"Serum resistin is associated with high risk in patients with congestive heart failure--a novel link between metabolic signals and heart failure","volume":"71","author":"Takeishi","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2019.10.003_bib0435","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jacc.2008.07.073","article-title":"Resistin, adiponectin, and risk of heart failure the Framingham offspring study","volume":"53","author":"Frankel","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0440","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/nm.4185","article-title":"Signals from the gut microbiota to distant organs in physiology and disease","volume":"22","author":"Schroeder","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2019.10.003_bib0445","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/cmi.12501","article-title":"The intestinal epithelium as guardian of gut barrier integrity","volume":"17","author":"Zhang","year":"2015","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0450","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12876-014-0189-7","article-title":"Intestinal permeability--a new target for disease prevention and therapy","volume":"14","author":"Bischoff","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0455","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cmet.2015.05.020","article-title":"cell inflammation in human obesity correlates with decreased enterocyte insulin signaling","volume":"22","author":"Monteiro-Sepulveda","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2019.10.003_bib0460","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/path.5134","article-title":"Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes","volume":"246","author":"Genser","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0465","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.06.1179","article-title":"Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia","volume":"64","author":"Sandek","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0470","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","article-title":"Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis","volume":"38","author":"Schiattarella","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2019.10.003_bib0475","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2007.07.016","article-title":"Altered intestinal function in patients with chronic heart failure","volume":"50","author":"Sandek","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0480","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ehf2.12155","article-title":"Heart failure is associated with depletion of core intestinal microbiota","volume":"4","author":"Luedde","year":"2017","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.diabet.2019.10.003_bib0485","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature12506","article-title":"Richness of human gut microbiome correlates with metabolic markers","volume":"500","author":"Le Chatelier","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.diabet.2019.10.003_bib0490","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jchf.2015.10.009","article-title":"Pathogenic gut flora in patients with chronic heart failure","volume":"4","author":"Pasini","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.diabet.2019.10.003_bib0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174099","article-title":"Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure","volume":"12","author":"Kamo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2019.10.003_bib0500","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jacc.2017.12.057","article-title":"Gut microbiota signature in heart failure defined from profiling of 2 independent cohorts","volume":"71","author":"Kummen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0505","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1253\/circj.CJ-17-1285","article-title":"Non-ischemic heart failure with reduced ejection fraction is associated with altered intestinal microbiota","volume":"82","author":"Katsimichas","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2019.10.003_bib0510","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41598-017-18756-2","article-title":"Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients","volume":"8","author":"Cui","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2019.10.003_bib0515","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41569-018-0108-7","article-title":"Dietary metabolism, the gut microbiome, and heart failure","volume":"16","author":"Tang","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0520","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2014.02.617","article-title":"Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis","volume":"64","author":"Tang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0525","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/heartjnl-2015-308826","article-title":"Trimethylamine N-oxide and prognosis in acute heart failure","volume":"102","author":"Suzuki","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.diabet.2019.10.003_bib0530","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart: the cytokine hypothesis revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2019.10.003_bib0535","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","article-title":"Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST)","volume":"103","author":"Deswal","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2019.10.003_bib0540","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/01.CIR.97.14.1382","article-title":"Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats","volume":"97","author":"Bozkurt","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2019.10.003_bib0545","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/01.RES.81.4.627","article-title":"Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha","volume":"81","author":"Kubota","year":"1997","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2019.10.003_bib0550","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2015.09.017","article-title":"Intersections between microbiome and heart failure: revisiting the gut hypothesis","volume":"21","author":"Nagatomo","year":"2015","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabet.2019.10.003_bib0555","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-med-060513-093205","article-title":"The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases","volume":"66","author":"Brown","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.diabet.2019.10.003_bib0560","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvz135","article-title":"The intestinal microbiota and cardiovascular disease","author":"Katsimichas","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2019.10.003_bib0565","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cyto.2008.01.006","article-title":"LPS\/TLR4 signal transduction pathway","volume":"42","author":"Lu","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.diabet.2019.10.003_bib0570","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","article-title":"The inflammatory response in myocardial injury, repair, and remodelling","volume":"11","author":"Frangogiannis","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0575","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0140-6736(98)09286-1","article-title":"Endotoxin and immune activation in chronic heart failure: a prospective cohort study","volume":"353","author":"Niebauer","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2019.10.003_bib0580","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2010.12.016","article-title":"Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure","volume":"157","author":"Sandek","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0585","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1388-9842(03)00104-1","article-title":"Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure","volume":"5","author":"Peschel","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2019.10.003_bib0590","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/SHK.0b013e3181a2bcd6","article-title":"Systemic inflammation increases intestinal permeability during experimental human endotoxemia","volume":"32","author":"Hietbrink","year":"2009","journal-title":"Shock"},{"key":"10.1016\/j.diabet.2019.10.003_bib0595","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1253\/circj.CJ-15-0749","article-title":"Role of gut-derived protein-bound uremic toxins in cardiorenal syndrome and potential treatment modalities","volume":"79","author":"Lekawanvijit","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2019.10.003_bib0600","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1681\/ASN.2014060543","article-title":"Klotho protects against indoxyl sulphate-induced myocardial hypertrophy","volume":"26","author":"Yang","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0605","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/CIRCULATIONAHA.116.024545","article-title":"High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice","volume":"135","author":"Marques","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2019.10.003_bib0610","doi-asserted-by":"crossref","first-page":"G900","DOI":"10.1152\/ajpgi.00265.2013","article-title":"Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids","volume":"305","author":"den Besten","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0615","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature11450","article-title":"A metagenome-wide association study of gut microbiota in type 2 diabetes","volume":"490","author":"Qin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.diabet.2019.10.003_bib0620","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.diabet.2019.10.003_bib0625","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cardfail.2017.06.007","article-title":"Increased secondary\/primary bile acid ratio in chronic heart failure","volume":"23","author":"Mayerhofer","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabet.2019.10.003_bib0630","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/CIRCRESAHA.110.226928","article-title":"Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB","volume":"108","author":"Gordon","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2019.10.003_bib0635","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacc.2011.10.880","article-title":"Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial","volume":"59","author":"von Haehling","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0640","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1056\/NEJMoa1014296","article-title":"Changes in diet and lifestyle and long-term weight gain in women and men","volume":"364","author":"Mozaffarian","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2019.10.003_bib0645","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jchf.2017.09.020","article-title":"Adherence to Mediterranean diet and all-cause mortality after an episode of acute heart failure: results of the MEDIT-AHF study","volume":"6","author":"Miro","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.diabet.2019.10.003_bib0650","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijcard.2014.11.034","article-title":"Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial","volume":"179","author":"Costanza","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0655","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ehf2.12332","article-title":"Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial","volume":"5","author":"Mayerhofer","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.diabet.2019.10.003_bib0660","first-page":"383","article-title":"Treating obesity and metabolic syndrome with fecal microbiota transplantation","volume":"89","author":"Marotz","year":"2016","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.diabet.2019.10.003_bib0665","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.cell.2015.11.055","article-title":"Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.diabet.2019.10.003_bib0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041281","article-title":"Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate","volume":"7","author":"Lekawanvijit","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2019.10.003_bib0675","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/eurheartj\/ehp574","article-title":"Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?","volume":"31","author":"Lekawanvijit","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2019.10.003_bib0680","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2019.10.003_bib0685","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/clc.22719","article-title":"Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2)","volume":"40","author":"Van Tassell","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.diabet.2019.10.003_bib0690","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circ Heart Fail"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363619301594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363619301594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:56:35Z","timestamp":1761130595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363619301594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1262363619301594"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2019.10.003","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The gut microbiota and diabetic cardiomyopathy in humans","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2019.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}